{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:47:43Z","timestamp":1786632463315,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti\u2013glutamic acid decarboxylase (GAD) antibody\u2013associated neurological syndromes encompass a heterogeneous group of immune-mediated disorders in which ocular involvement is increasingly recognized but remains insufficiently characterized. Data on clinical features, neuroimaging, and longitudinal ocular motor findings are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed four patients diagnosed with anti-GAD antibody\u2013associated neurological syndromes presenting with ocular manifestations at our center between 2019 and 2025. Clinical features, ocular motor findings, laboratory and neuroimaging results, treatment, and outcomes were collected. Longitudinal video-oculography (VOG) was analyzed in one patient. A literature review was performed to summarize reported ocular and vestibulo-ocular abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All four patients (2 males, 2 females; onset age 53\u201368 years) exhibited ocular symptoms, three presented with ocular symptoms early in the disease course; however, in one case (Case 4), the temporal association between the initial ocular symptom and the final diagnosis remained uncertain. Diplopia, nystagmus, and ptosis were the predominant findings. Early brain and orbital Magnetic Resonance Imaging (MRI) were unremarkable, while cerebellar atrophy developed in one patient during relapse. All patients were positive for serum anti-GAD65 antibodies; one also had anti-titin antibodies with elevated creatine kinase(CK). VOG in one patient demonstrated worsening saccadic velocity and pursuit gain during relapse, consistent with cerebellar dysfunction. Literature review of 61 articles showed that diplopia and nystagmus were the most frequently reported features, with characteristic vestibulo-ocular abnormalities including multistep saccades and square-wave oscillations. Based on clinical and literature findings, we further identified recurrent oculomotor patterns across cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ocular symptoms may represent early clinical features of anti-GAD antibody\u2013associated neurological syndromes, although the temporal relationship may vary across patients and should be interpreted with caution in atypical cases. Downbeat nystagmus may serve as an early marker of cerebellar involvement. Longitudinal VOG provides objective insights into disease evolution. Importantly, we propose a structured oculomotor phenotype framework and highlight longitudinal VOG as a tool for tracking dynamic cerebellar dysfunction, which may facilitate earlier recognition and monitoring of disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05014-0","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:54:35Z","timestamp":1781186075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oculomotor phenotypes and longitudinal video-oculography dynamics in anti-GAD65 antibody\u2013associated neurological syndromes: a case series and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Feifei","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"5","key":"5014_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1212\/WNL.57.5.780","volume":"57","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001;57(5):780\u20134.","journal-title":"Neurology"},{"issue":"4","key":"5014_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.21917","volume":"67","author":"MP Malter","year":"2010","unstructured":"Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470\u20138.","journal-title":"Ann Neurol"},{"key":"5014_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.seizure.2015.05.017","volume":"30","author":"MP Malter","year":"2015","unstructured":"Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57\u201363.","journal-title":"Seizure"},{"issue":"2","key":"5014_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12311-015-0664-x","volume":"15","author":"H Mitoma","year":"2016","unstructured":"Mitoma H, Adhikari K, Aeschlimann D, Chattopadhyay P, Hadjivassiliou M, Hampe CS, et al. Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias. Cerebellum. 2016;15(2):213\u201332.","journal-title":"Cerebellum"},{"key":"5014_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1196\/annals.1325.042","volume":"1039","author":"C Tilikete","year":"2005","unstructured":"Tilikete C, Vighetto A, Trouillas P, Honnorat J. Potential role of anti-GAD antibodies in abnormal eye movements. Ann N Y Acad Sci. 2005;1039:446\u201354.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"5014_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s00415-013-7110-0","volume":"260","author":"R Dubbioso","year":"2013","unstructured":"Dubbioso R, Marcelli V, Manganelli F, Iodice R, Esposito M, Santoro L. Anti-GAD antibody ocular flutter: expanding the spectrum of autoimmune ocular motor disorders. J Neurol. 2013;260(10):2675\u20137.","journal-title":"J Neurol"},{"issue":"6","key":"5014_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clineuro.2008.03.005","volume":"110","author":"I Markakis","year":"2008","unstructured":"Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg. 2008;110(6):619\u201321.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"5014_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12311-018-0972-z","volume":"18","author":"D Feldman","year":"2019","unstructured":"Feldman D, Otero-Millan J, Shaikh AG. Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies. Cerebellum. 2019;18(2):287\u201390.","journal-title":"Cerebellum"},{"issue":"3","key":"5014_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/aian.AIAN_470_20","volume":"24","author":"RR Mahale","year":"2021","unstructured":"Mahale RR, Dutta D, Kovoor J, Mailankody P, Padmanabha H, Mathuranath PS. Upbeat Nystagmus in Late Onset Cerebellar Ataxia: Think of Anti-Glutamate Decarboxylase 65 Antibody-Associated Cerebellar Ataxia. Ann Indian Acad Neurol. 2021;24(3):441\u20133.","journal-title":"Ann Indian Acad Neurol"},{"key":"5014_CR10","doi-asserted-by":"publisher","first-page":"1256089","DOI":"10.3389\/fimmu.2023.1256089","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue J, Lian C, Long Y, He D. Case Report: Extraocular muscles paralysis associated with GAD65 antibody: a case series study. Front Immunol. 2023;14:1256089.","journal-title":"Front Immunol"},{"issue":"4","key":"5014_CR11","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1097\/WNO.0000000000001084","volume":"41","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tourkevich R, Bosley J, Gold DR, Newsome SD. Ocular Motor and Vestibular Characteristics of Antiglutamic Acid Decarboxylase-Associated Neurologic Disorders. J Neuroophthalmol. 2021;41(4):e665\u201371.","journal-title":"J Neuroophthalmol"},{"issue":"1\u20132","key":"5014_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2015.10.024","volume":"359","author":"TC Vale","year":"2015","unstructured":"Vale TC, Pedroso JL, Alqu\u00e9res RA, Dutra LA, Barsottini OG. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies. J Neurol Sci. 2015;359(1\u20132):21\u20133.","journal-title":"J Neurol Sci"},{"issue":"5","key":"5014_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604\u20137.","journal-title":"Stroke"},{"issue":"4","key":"5014_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"5014_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","volume":"92","author":"A Budhram","year":"2021","unstructured":"Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry. 2021;92(6):645\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5014_CR16","first-page":"1220","volume":"40","author":"N Shimizu","year":"2000","unstructured":"Shimizu N. [Neurology of eye movements]. Rinsho Shinkeigaku. 2000;40(12):1220\u20133.","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"5014_CR17","doi-asserted-by":"publisher","first-page":"e70237","DOI":"10.1111\/cns.70237","volume":"31","author":"Z Qiu","year":"2025","unstructured":"Qiu Z, Xu F, Zhang M, Yang X, Han Y, Li D, et al. Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China. CNS Neurosci Ther. 2025;31(2):e70237.","journal-title":"CNS Neurosci Ther"},{"key":"5014_CR18","doi-asserted-by":"publisher","first-page":"116506","DOI":"10.1016\/j.jns.2019.116506","volume":"408","author":"S Kodama","year":"2020","unstructured":"Kodama S, Tokushige SI, Sugiyama Y, Sato K, Otsuka J, Shirota Y, et al. Rituximab improves not only back stiffness but also stiff eyes in stiff person syndrome: Implications for immune-mediated treatment. J Neurol Sci. 2020;408:116506.","journal-title":"J Neurol Sci"},{"issue":"1","key":"5014_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","volume":"76","author":"S Thomas","year":"2005","unstructured":"Thomas S, Critchley P, Lawden M, Farooq S, Thomas A, Proudlock FA, et al. Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymoma. J Neurol Neurosurg Psychiatry. 2005;76(1):141\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"5014_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/WNO.0000000000000275","volume":"35","author":"C Brokalaki","year":"2015","unstructured":"Brokalaki C, Kararizou E, Dimitrakopoulos A, Evdokimidis I, Anagnostou E. Square-Wave Ocular Oscillation and Ataxia in an Anti-GAD-Positive Individual With Hypothyroidism. J Neuroophthalmol. 2015;35(4):390\u20135.","journal-title":"J Neuroophthalmol"},{"key":"5014_CR21","doi-asserted-by":"publisher","first-page":"529985","DOI":"10.3389\/fneur.2020.529985","volume":"11","author":"K Godbe","year":"2020","unstructured":"Godbe K, Malaty G, Wenzel A, Nazeer S, Grider DJ, Kinsey A. McArdle Disease vs. Stiff-Person Syndrome: A Case Report Highlighting the Similarities Between Two Rare and Distinct Disorders. Front Neurol. 2020;11:529985.","journal-title":"Front Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05014-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:59:22Z","timestamp":1786629562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5014"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05014-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional ethics committee of our center(Beijing Tongren Hospital, Capital Medical University) and conducted according to the Declaration of Helsinki. Ethical number: TRECKY2021-179.Written and informed consent was obtained from all patients and their families included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final manuscript. Written and informed consent was obtained from all patients and their families included in the study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"514"}}